What is the proper dosage and usage of quetiapine (Seroquel) for treating schizophrenia and bipolar disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Quetiapine (Seroquel) Dosage and Usage for Schizophrenia and Bipolar Disorder

For treating schizophrenia and bipolar disorder, quetiapine should be initiated at low doses (25-50 mg/day) and gradually titrated to therapeutic doses of 300-800 mg/day for schizophrenia and 300-600 mg/day for bipolar depression, administered in divided doses.

Dosing for Schizophrenia

Initial Dosing and Titration

  • Start with 25-50 mg/day and increase gradually to target dose 1, 2
  • Titrate to 300-400 mg/day by day 4, divided into two daily doses 2
  • Further titration based on clinical response and tolerability within 150-750 mg/day range 2

Maintenance Dosing

  • Recommended target dosage: 300-450 mg/day administered as 2 doses 2
  • For patients not responding to lower doses, consider increasing to 400-800 mg/day 3
  • Maximum FDA-approved dose is 800 mg/day, though some treatment-resistant cases may require higher doses under specialist supervision 2, 4

Special Populations

  • Elderly patients: Start with 25 mg/day and increase by 25-50 mg daily to an effective dose, which will likely be lower than standard adult dosing 2
  • Hepatic impairment: Start with 25 mg/day and titrate slowly 1
  • Adolescents (13-17 years): FDA approved for schizophrenia with adjusted dosing due to different pharmacokinetics 1

Dosing for Bipolar Disorder

Bipolar Depression

  • Initial dose: 50 mg on day 1, increased to 100 mg on day 2, then 200 mg on day 3, and 300 mg on day 4 1, 5
  • Target dose: 300 mg/day (no additional benefit demonstrated with 600 mg/day) 5
  • Administer once daily at bedtime 5

Bipolar Mania

  • Initial dose: 50 mg twice daily on day 1, increased to 100 mg twice daily on day 2,150 mg twice daily on day 3, and 200 mg twice daily on day 4 6
  • Target dose: 400-800 mg/day in divided doses 6, 1
  • For children/adolescents (10-17 years): FDA approved with adjusted dosing 1

Administration Considerations

  • Immediate-release formulation is typically administered twice daily 2
  • Extended-release formulation can be administered once daily, typically at bedtime 5
  • Can be taken with or without food 1
  • Oral route only for standard treatment of schizophrenia and bipolar disorder 6

Monitoring and Safety

  • No routine blood monitoring required (unlike clozapine) 3
  • Monitor for sedation, orthostatic hypotension, and dizziness, especially during initial titration 6
  • Less likely to cause extrapyramidal symptoms (EPS) than typical antipsychotics 3
  • Monitor for metabolic effects including weight gain and changes in blood glucose and lipid parameters 5
  • Reduce dose in patients with hepatic impairment 1

Common Side Effects

  • Sedation (use caution when driving or operating machinery) 6, 5
  • Dry mouth 5
  • Dizziness 6
  • Orthostatic hypotension, especially during initial titration 6
  • Constipation 5
  • Weight gain (though less than some other atypical antipsychotics) 5

Clinical Pearls

  • Quetiapine has lower risk of extrapyramidal symptoms compared to typical antipsychotics and some atypical antipsychotics 6, 3
  • For treatment-resistant schizophrenia, consider clozapine before using quetiapine doses above 800 mg/day 6
  • In bipolar depression, quetiapine monotherapy has demonstrated efficacy without increasing risk of switching to mania 5
  • Avoid abrupt discontinuation; taper gradually to minimize withdrawal symptoms 5
  • Potential for abuse has been reported, particularly in patients with substance use disorders 7

Duration of Treatment

  • For schizophrenia, continue treatment for at least 12 months after remission of symptoms 6
  • For bipolar disorder, maintenance treatment should continue for at least 2 years after the last episode 6
  • Long-term treatment decisions should be made in consultation with a mental health specialist 6

References

Research

Review of quetiapine and its clinical applications in schizophrenia.

Expert opinion on pharmacotherapy, 2000

Research

Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up.

International journal of psychiatry in clinical practice, 2005

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Quetiapine in substance use disorders, abuse and dependence possibility: a review].

Turk psikiyatri dergisi = Turkish journal of psychiatry, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.